ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says

ArriVent BioPharma (NASDAQ:AVBP) had its price objective upped by research analysts at HC Wainwright from $42.00 to $44.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 87.79% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Truist Financial began coverage on shares of ArriVent BioPharma in a research report on Tuesday, November 25th. They set a “buy” rating and a $43.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Wednesday, January 21st. Cantor Fitzgerald initiated coverage on ArriVent BioPharma in a report on Monday, December 22nd. They set an “overweight” rating for the company. Citigroup lowered their price objective on ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating for the company in a research report on Tuesday, November 11th. Finally, Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.11.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $23.43 on Friday. The company has a market capitalization of $967.19 million, a PE ratio of -5.31 and a beta of 0.99. The company has a 50-day simple moving average of $22.20 and a two-hundred day simple moving average of $20.93. ArriVent BioPharma has a one year low of $15.47 and a one year high of $27.22.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, equities analysts predict that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ArriVent BioPharma

A number of large investors have recently made changes to their positions in AVBP. Squarepoint Ops LLC increased its position in shares of ArriVent BioPharma by 1,009.1% in the 2nd quarter. Squarepoint Ops LLC now owns 204,355 shares of the company’s stock valued at $4,449,000 after acquiring an additional 185,929 shares during the period. Fund 1 Investments LLC acquired a new stake in ArriVent BioPharma during the 2nd quarter worth about $11,503,000. AXQ Capital LP purchased a new stake in ArriVent BioPharma during the 2nd quarter valued at about $277,000. AlphaQuest LLC purchased a new stake in ArriVent BioPharma during the 3rd quarter valued at about $765,000. Finally, Corient IA LLC acquired a new position in shares of ArriVent BioPharma in the third quarter valued at about $618,000. 9.48% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.